The “Australia and New Zealand prothrombin complex concentrate market” size is expected to experience considerable growth by reaching USD 40.4 million by 2027 while exhibiting a CAGR of 10.9% between 2020 and 2027. This growth is attributable to the increasing consumption of Vitamin K antagonists such as warfarin that is likely to surge the demand for advanced prothrombin complex concentrates in Australia and New Zealand. This information is published by Fortune Business Insights in its latest report, titled, “Australia and New Zealand Prothrombin Complex Concentrate Market Size, Share & Covid-19 Impact Analysis, By Product (4-factor PCC and 3-factor PCC), By Application (Acquired Coagulation Factor Deficiency and Congenital Coagulation Factor Deficiency and By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics, and Others), 2020-2027.” The report further observes that the market stood at USD 17.8 million in 2019.

The COVID-19 pandemic has affected several economies that are facing unprecedented loss. Owing to the lockdown announced by the government agencies and reduced labor force, several industries have been on a standstill with limited operational activities. However, a proactive combined effort from the government and other industries is anticipated to bring the economy back on track and aid in the industrial activities returning to pre-pandemic levels.

Prothrombin complex concentrate (PCC) is manufactured after the removal of factor XI and antithrombin through a process of ion-exchange chromatography from the cryoprecipitate supernatant of large plasma pools. These concentrates are extensively used to treat and further prevent bleeding in the case of hemophilia B if a pure factor IX is not present.

Major Australia and New Zealand Prothrombin Complex Concentrate Market Key players covered in the report include:

  • CSL Limited (Melbourne, Australia)
  • Grifols, S.A. (Barcelona, Spain)
  • Octapharma AG (Lachen, Switzerland)
  • Kedrion S.p.A (Lucca, Italy)
  • Sanquin (Amsterdam, The Netherlands)
  • Takeda Pharmaceutical Company Limited (Mumbai, India)
  • Other Prominent Players

Get Request a Sample Copy of the Australia and New Zealand Prothrombin Complex Concentrate Report:

Our research methodology is robust and includes data triangulation based on bottom-up and top-down approaches. We validated the approximate market number with the help of primary research. Secondary research was conducted to find out detailed information about mergers and acquisitions, collaborations, joint ventures, and agreements. At the same time, we have derived significant information about the market dynamics associated with growth drivers, trends, and obstacles.

It offers figurative estimations for upcoming years on the basis of the recent developments and historic data. For gathering information and estimating revenue for all segments, researchers have used top-down and bottom-up approaches. On the basis of data collected from primary and secondary research and trusted data sources the report will help both existing and new aspirants for market to figure out and study the market’s needs, market size, and competition.

Australia and New Zealand Prothrombin Complex Concentrate Market Analysis 2021:


Increasing Consumption of Vitamin K Antagonists to Surge Demand

As per an article published by The National Center for Biotechnology Information (NCBI), it is anticipated that at least 1%-2% of the total population takes warfarin therapy. Owing to its affordability, warfarin is widely consumed, however, this anticoagulation agent may lead to fatal bleeding disorders due to over-dependency. Therefore, this is expected to boost the demand for advanced prothrombin complex concentrates that aid in effective treatment and prevention of bleeding disorders. Moreover, supportive government initiatives to promote awareness regarding the adoption of PCC is expected to contribute to the Australia and New Zealand prothrombin complex concentrate market growth in the forthcoming years.


Hospitals and Ambulatory Surgical Centers to Hold Largest Market Share

Based on end-user, the hospitals and ambulatory surgical centers segment is expected to showcase considerable growth during the forecast period. This growth is ascribable to the factors such as the increasing number of invasive surgeries and the easy availability of prothrombin complex concentrates across several healthcare institutions in Australia and New Zealand.

Click here to get the short-term and long-term impact of COVID-19 on this Market.

Please visit: